GSK Magrit
A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with MAGE-A3 Positive Non-Small Cell Lung Cancer.
A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with MAGE-A3 Positive Non-Small Cell Lung Cancer.